Table 1.
Patient Characteristics: discovery and validation sets for isomiR profiling
| Discovery set | Validation set | |||||
|---|---|---|---|---|---|---|
| Normal Colon | Advanced Adenomab | CRC | Normal Colon | Advanced Adenomab | CRC | |
| No. of cases | 20 | 26 | 35 | 30 | 20 | 40 |
| Age | ||||||
| Mean ± SD | 62 ± 5 | 62 ± 11 | 59 ± 10 | 61 ± 13 | 66 ± 11 | 70 ± 13 |
| Gender, number (%) | ||||||
| Female | 9 (45) | 13 (50) | 17 (49) | 15 (50) | 6 (30) | 22 (55) |
| Location, number (%) | ||||||
| Proximala | 13 (50) | 17 (49) | 13 (65) | 17 (43) | ||
| TNM stage, number (%) | ||||||
| I | 6 (17) | 1 (3) | ||||
| II | 10 (29) | 12 (30) | ||||
| III | 15 (43) | 26 (65) | ||||
| IV | 4 (11) | 1 (3) | ||||
aProximal lesions include tumors at or proximal to the splenic flexure, and distal lesions are those distal to the splenic flexure
bAdvanced adenoma includes 1) adenoma measuring ≥1 cm in the greatest dimension, with high-grade dysplasia, or with ≥25% villous histologic features, and 2) Sessile serrated adenoma ≥ 1 cm